From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

QuantuMDx Raises Funds to Advance Handheld DNA Sequencer

by Global Biodefense Staff
June 4, 2014

Handheld molecular diagnostics device developer QuantuMDx Group this week announced it has closed an $8.42M funding round via philanthropist private investors and the University of Newcastle upon Tyne, following the recent publicity success of its Indiegogo crowdfunding campaign.

The funds will be used to further optimize and trial Q-POC, QuantuMDx’s handheld DNA sequencer & genotyping device, in addition to extending the company’s assay pipeline, expanding its research teams and appointing an Advisory Board.

“2014 will be an immensely exciting year for QuantuMDx as we demonstrate, in real-time, our ability to undertake 15 minute sample-to-result analysis for complex molecular diagnostics,” said Elaine Warburton, CEO and Co-Founder. “Later this year when we formally unveil our prototype, we anticipate much interest from Life Science and Pharma companies seeking a low cost, high quality POC platform for diagnostics and to support drug development.”

“Most of the basic research was completed last year and we moved into an engineering phase to integrate these technologies and chemistries at the beginning of this year. We are now moving into the testing phase of our alpha prototype,” says Jonathan O’Halloran, CSO, inventor and Co-Founder. “Excitingly, we envisage these devices to be readily distributed globally due to their low cost, fast turn-around times and referral standard testing. With networked devices all over the world we will have a platform to monitor emerging pathogens and drug resistance hotspots in real-time; a concept we like to call the Internet of Life”.

Field trials will commence early 2015 for Q-POC’s first assays in malaria speciation and drug resistance, in partnership with NGOs and hospitals in several African countries, and a companion diagnostic for warfarin within the UK’s National Health Service, in anticipation of a commercial launch later in 2015.

From Our Partners
Tags: POC Diagnostics

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC